Composition for noninvasive screening of early lung cancer and application of composition
A composition and lung cancer technology, applied in the direction of microbial measurement/testing, biochemical equipment and methods, etc., can solve the problem of less circulating DNA in tumors, and achieve the effects of easy interpretation, simple operation, and low requirements for instruments
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0061] Detection of methylation of SHOX2 and PTGER4 genes in plasma cell-free DNA of patients with stage I lung cancer.
[0062] The components of the kit are as follows:
[0063]
[0064] Plasma samples from 5 healthy individuals and 5 tumor plasma samples with known pathological information as stage I lung cancer were selected.
[0065] 1. Extract free DNA from the above 10 plasma samples.
[0066] 2. After the extraction of free DNA is completed, bisulfite conversion is performed on the extracted DNA, and the unmethylated cytosine (C) is converted into uracil (U), while the methylated cytosine (C) remains unchanged. Purified Bis-DNA was obtained.
[0067] 3. Prepare PCR reaction solution: DNA polymerase, dNTPs, Mg 2+ , 10×DNA polymerase buffer, SHOX2 and PTGER4 gene 1 primer probe, SHOX2 and PTGER4 gene 2 primer probe, SHOX2 and PTGER4 gene 3 primer probe, internal reference gene primer probe, SHOX2 and PTGER4 gene 1 degenerate blocking primer , SHOX2 and PTGER4 gene...
Embodiment 2
[0089] Plasma samples from 93 early lung cancer patients (27 cases at stage 0 and 66 cases at stage I) from Shanghai Lung Hospital and 100 normal human plasma samples from Shandong Qilu Hospital were collected, and SHOX2 and PTGER4 genes were tested for these 193 plasma samples For the detection of methylation, the specific operation steps are as described in Example 1. Among the detection results of 100 normal plasma samples, the difference between the target gene 1 / 2 / 3Ct value and the internal reference gene Ct value in 95 samples was greater than 8, and the specificity reached 95%. For 93 early lung cancer plasma samples, 88 The difference between the target gene 1 / 2 / 3Ct value and the internal reference gene Ct value is less than 8, and its sensitivity reaches 95%, among which 0 stage lung cancer is 89%, and stage I lung cancer is 97%.
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com